Swallow Madisen A, Fan Ryan, Cohen Jeffrey M, Bunick Christopher G
Yale School of Medicine, New Haven, CT 06510, USA.
Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA.
Antibiotics (Basel). 2022 Jul 30;11(8):1032. doi: 10.3390/antibiotics11081032.
Almost 1 billion people worldwide have acne, and oral tetracyclines, including doxycycline and minocycline, are effective and frequently prescribed treatments for acne. However, there is growing concern for the development of antibiotic resistance with such widespread utilization by dermatologists. Additionally, tetracyclines are known to have various potential side effects, including gut dysbiosis, gastrointestinal upset, photosensitivity, dizziness, and vertigo. However, in 2018 a novel narrow-spectrum tetracycline, sarecycline, was Food and Drug Administration-approved to treat moderate-to-severe acne vulgaris in patients 9-years-old and above. Sarecycline was designed to target , the pathogenic bacterium in acne vulgaris, which may reduce the risk of resistance. This paper examines the growing concerns of antibiotic resistance due to oral tetracycline usage in the treatment of acne vulgaris, with a focus on the promising third-generation, narrow-spectrum tetracycline, sarecycline.
全球近10亿人患有痤疮，口服四环素类药物，包括强力霉素和米诺环素，是治疗痤疮的有效且常用的药物。然而，皮肤科医生如此广泛地使用这类药物，人们对抗生素耐药性的发展越来越担忧。此外，已知四环素类药物有各种潜在副作用，包括肠道菌群失调、胃肠道不适、光敏反应、头晕和眩晕。然而，2018年一种新型窄谱四环素类药物——丝丽环素被美国食品药品监督管理局批准用于治疗9岁及以上患者的中度至重度寻常痤疮。丝丽环素旨在靶向寻常痤疮中的病原菌，这可能会降低耐药风险。本文探讨了口服四环素治疗寻常痤疮引起的抗生素耐药性问题日益受到关注，重点关注有前景的第三代窄谱四环素类药物丝丽环素。
